Skip to content

Ardelyx ARDX Deferred Tax Assets, Valuation Allowance

Deferred Tax Assets, Valuation Allowance at other companies

Bausch Health Companies logo
Bausch Health CompaniesBHC
Mineralys Therapeutics, Inc. logo
Mineralys Therapeutics, Inc.MLYS

Other financials

Income statement

See full
Revenue$94.5M+27.5%
Gross profit$89.7M+45.1%
Operating income-$32.8M+9.8%
Net income-$37.6M+8.6%
EPS (diluted)-$0.15+11.8%

Balance sheet

See full
Cash & equivalents$31.2M+1.3%
Total debt$208.3M+34.3%
Total equity$148.6M+2.0%
Total assets$504.5M+23.0%

Cash flow

See full
Operating cash flow-$32.2M+16.2%
CapEx$69.0K-78.8%
Free cash flow-$32.3M+16.7%

Valuation

See full
Market cap$1.53B+25.5%
Enterprise value$1.71B+27.1%
P/S3.6×+0.2×

Profitability

See full
Gross margin92.5%+7.9pp
Operating margin-25.4%
Net margin-13.6%
FCF margin-40.9%

Returns & leverage

See full
Return on equity-39.5%
Debt / equity1.4×+0.3×
Current ratio3.5×-0.6×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsValuationAllowance.

The official record: Ardelyx’s 10-K, filed February 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ardelyx's deferred tax assets, valuation allowance.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ardelyx's deferred tax assets, valuation allowance?
Ardelyx (ARDX) reported deferred tax assets, valuation allowance of $219.59M in Q4 2025.
How has Ardelyx's deferred tax assets, valuation allowance changed year-over-year?
Ardelyx's deferred tax assets, valuation allowance increased by 5.3% year-over-year, from $208.57M to $219.59M.
What is the long-term trend for Ardelyx's deferred tax assets, valuation allowance?
Over 5 years (2020 to 2025), Ardelyx's deferred tax assets, valuation allowance has grown at a 12.2% compound annual growth rate (CAGR), from $123.4M to $219.59M.